Copyright ©The Author(s) 2016.
World J Hepatol. Mar 18, 2016; 8(8): 385-394
Published online Mar 18, 2016. doi: 10.4254/wjh.v8.i8.385
Table 2 Recommendations for treatment and follow-up in different clinical scenarios, according to Asian Pacific Association for the Study of the Liver, American Association for the Study of Liver Disease and European Association for the Study of the Liver guidelines
Recommendations in different clinical scenarios
HBsAg (+) HBV DNA2000 U/mLHBsAg (+) HBV DNA < 2000 U/mLHBsAg (-) antiHBc (+)HBsAg (-) antiHBc (-) antiHBs (-)HBV-HCC TACE
ActionTreatTreatClose mon/treat if HBV DNA (+) or rituximab/stem cell transplant1VaccinationTreat3
OnsetBefore ISBefore ISBefore IS-Before IS
Duration6-12 mo (except CI)6-12 mo (except CI)6-12 mo--
DrugShort IS: LAM (LdT) preferred ETV/TDFShort IS: LAM (LdT) (ETV/TDF)Short IS: LAM (LdT) (ETV/TDF)-LAM (ETV/TDF)
Follow-up--Every 1-3 mo/treat if HBV DNA (+)2--